Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : Plans to Raise $166 Million in India IPO

share with twitter share with LinkedIn share with facebook
07/12/2020 | 08:35pm EDT

By P.R. Venkat

Shanghai Fosun Pharmaceutical (Group) Co. (2196.HK) said it is planning to raise as much as 12.50 billion rupees ($166.31 million) through an initial public offering of its unit, Gland Pharma Group, in India.

The company is planning to sell up to 34.86 million shares will be traded on the National Stock Exchange and Bombay Stock Exchange, Fosun Pharma said in a filing late Friday.

The company said that it has already filed a draft prospectus with the Securities and Exchange Board of India as well as the two Indian stock exchanges.

Gland Pharma, established in 1974, is in the business of developing and manufacturing small molecule injectable generic drugs.

 

Write to P.R. Venkat at venkat.pr@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
FOSUN INTERNATIONAL LIMITED -0.75% 9.25 End-of-day quote.-18.57%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. -3.08% 58.2 End-of-day quote.118.80%
share with twitter share with LinkedIn share with facebook
Toute l'actualité sur SHANGHAI FOSUN PHARMACEUTI
04:38aSHANGHAI FOSUN PHARMACEUTICAL : Connected transaction - entering into the capita..
PU
08/12SHANGHAI FOSUN PHARMACEUTICAL : Overseas Regulatory Announcement - Announcement ..
PU
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/06AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
08/06AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
08/05BIONTECH : Shanghai Fosun Pharma Dose Participants in China Covid-19 Vaccine Tri..
DJ
08/05SHANGHAI FOSUN PHARMACEUTICAL : BioNTech, Fosun launch another COVID-19 vaccine ..
RE
07/30SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
07/27SHANGHAI FOSUN PHARMACEUTICAL : Says Covid-19 Vaccine in Phase 1 Clinical Trial
DJ
More news
Financials
Sales 2020 32 396 M 4 661 M 4 661 M
Net income 2020 3 545 M 510 M 510 M
Net Debt 2020 13 549 M 1 949 M 1 949 M
P/E ratio 2020 41,7x
Yield 2020 0,70%
Capitalization 134 B 19 288 M 19 290 M
EV / Sales 2020 4,56x
EV / Sales 2021 3,89x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 32,91 CNY
Last Close Price 58,20 CNY
Spread / Highest target -27,8%
Spread / Average Target -43,5%
Spread / Lowest Target -63,1%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors